Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Canc

Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT07810114 by Fudan University, with a registry enrolment figure of 52 participants, started 2026-08-28 and due to reach its primary completion in 2027-12-01. Interventions recorded: mFOLFOX6; Suvemcitug; Enlonstobart; Pelvic Chemoradiotherapy; Total Mesorectal Excision. Conditions listed: Rectal Cancer. Primary outcome: Pathologic Complete Response Rate. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.